GGrantIndex
← Leaderboards

Jun Wang

New York University School Of Medicine

$4,683,657
Attributed
$5,146,168
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY202125
$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,146,168 · 4

By mechanism

R01$2,416,835 · 2
R37$2,263,208 · 1
R21$466,125 · 1

Top collaborators

Most similar at New York University School Of Medicine

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Binding

Research focus

BindingImmunePd-1/Pd-L1LigandsResponsePathway InteractionsProgrammed Cell Death Protein 1ProgramsAntibodiesT-LymphocyteSignal TransductionCytokineReceptorEpitopesAffinityLeadGeneticImmune Checkpoint BlockadeGenome-WideImmune CheckpointInsightCheckpoint ReceptorsAntigen-Specific T CellsClinical Trials

Grant awards (11)

Machine learning for identifying antigen-antibody interactions from massive sequencing data$685,566
R01 · FY2025 · AI
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment$578,201
R01 · FY2025 · CA · contact PI
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy$571,456
R37 · FY2025 · CA · contact PI
Machine learning for identifying antigen-antibody interactions from massive sequencing data$8,200
R01 · FY2025 · AI
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment$549,292
R01 · FY2024 · CA · contact PI
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy$542,889
R37 · FY2024 · CA · contact PI
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment$595,576
R01 · FY2023 · CA · contact PI
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy$560,030
R37 · FY2023 · CA · contact PI
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy$588,833
R37 · FY2022 · CA · contact PI
Functional characterization of SARS-CoV-2 myeloid cell receptors as an immunopathogenic mechanisms of COVID-19$211,875
R21 · FY2022 · AI · contact PI
Functional characterization of SARS-CoV-2 myeloid cell receptors as an immunopathogenic mechanisms of COVID-19$254,250
R21 · FY2021 · AI · contact PI